In numerous studies, low CSF concentrations of the amyloid-beta peptide Aβ42 and elevated CSF levels of total Tau (tTau) and phosphorylated Tau (pTau) have been reported in patients with Alzheimer’s disease dementia or mild cognitive impairment due to AD [1, 2]. The gene discussed is MAPT; the disease is Cognitive impairment.